Abstract:
:Injecting behaviour in people who inject drugs is the main risk factor for hepatitis C virus (HCV) infection. Psychosocial factors such as having a partner who injects drugs and living with other drug users have been associated with increases in injecting risk behaviour. This study aimed to investigate changes in injecting behaviour during treatment for HCV infection whilst exploring the role of psychosocial factors on patients' injecting behaviour. Eradicate-C was a single-centred clinical trial (ISRCTN27564683) investigating the effectiveness of HCV treatment within the injecting drug-using population between 2012 and 2017. A total of 94 participants completed up to 24 weeks of treatment, with social and behavioural measures taken at different intervals throughout treatment. Data for 84 participants were analysed retrospectively to explore mechanisms of potential behavioural changes which had occurred during treatment. Injecting frequency reduced significantly between baseline (week 1) and every 4-weekly interval until week 26. Not being on opiate substitution therapy (OST) was associated with a statistically significant decrease in injecting frequency, χ2 (1) = 10.412, P = 0.001, as was having a partner who also used drugs, in particular when that partner was also on treatment for HCV infection, Z = -2.312, P = 0.021. Treating a hard-to-reach population for HCV infection is not only possible, but also bears health benefits beyond treatment of HCV alone. Enrolling couples on HCV treatment when partners are sero-concordant has shown enhanced benefits for reduction in injecting behaviour. Implications for practice are discussed.
journal_name
J Viral Hepatjournal_title
Journal of viral hepatitisauthors
Malaguti A,Sani F,Stephens BP,Ahmad F,Dugard P,Dillon JF,ERADICATE-C Study Group.doi
10.1111/jvh.13009subject
Has Abstractpub_date
2019-01-01 00:00:00pages
65-72issue
1eissn
1352-0504issn
1365-2893journal_volume
26pub_type
临床试验,杂志文章abstract::A randomized trial was conducted to assess the efficacy of interferon-alpha (IFN) daily in combination with ribavirin in 301 naïve patients with chronic hepatitis C (CHC). Patients were randomized to receive ribavirin 1.2 g daily (QD) for 48 weeks with either IFN 5 MU (thrice weekly) TIW for 8 weeks followed by IFN 3 ...
journal_title:Journal of viral hepatitis
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1046/j.1365-2893.2003.00439.x
更新日期:2003-09-01 00:00:00
abstract::With the advent of direct-acting antivirals (DAAs), the treatment of chronic hepatitis C virus (HCV) infection (CHC) has been revolutionized. Modern interferon- and potentially also ribavirin-free combinations consisting of 2 or 3 direct-acting antivirals (DAA) promise sustained virological response rates (SVR) of abo...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1111/jvh.12348
更新日期:2015-01-01 00:00:00
abstract::Chemotherapy for chronic hepatitis B virus (HBV) infection is inherently difficult for a variety of reasons that are related to unusual features of both HBV replication strategy and host cell metabolism. Previous attempts to treat chronic HBV infection using nucleoside analogues have been almost universally disappoint...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1046/j.1365-2893.1999.00151.x
更新日期:1999-03-01 00:00:00
abstract::Due to the severe shortage of the donor pool in China, a large number of patients are waiting for a suitable liver, or even worse lose the opportunity of transplantation. Reasonable use of hepatitis B surface antigen-positive (HBsAg-positive) donors is one possible strategy to increase the donor pool but the long-term...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,多中心研究
doi:10.1111/jvh.12972
更新日期:2018-12-01 00:00:00
abstract::Patients with chronic hepatitis B (HBsAg-positive) are at risk of viral reactivation if rituximab is administered without antiviral treatment, a potentially fatal complication of treatment. Patients with so-called 'resolved hepatitis B virus infection' (HBsAg-negative/cAb-positive) may also be at risk. We performed a ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,meta分析,评审
doi:10.1111/jvh.12402
更新日期:2015-10-01 00:00:00
abstract::Favourable efficacy and safety profiles for simeprevir in combination with pegylated interferon alpha (PEG-IFNα) and ribavirin (triple therapy) have been shown in clinical trials. This study was carried out to evaluate the effectiveness of simeprevir-based triple therapy for patients with prior telaprevir treatment fa...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,多中心研究
doi:10.1111/jvh.12427
更新日期:2015-12-01 00:00:00
abstract::We compared sustained virological response (SVR) in chronic hepatitis C patients with severe fibrosis treated with pegylated interferon (Peg-IFN) alpha-2b 1.5 microg/kg/week or 0.75 microg/kg/week in combination with ribavirin 800 mg/day for 48 weeks. This was a multicentre randomized controlled study. SVR was observe...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1111/j.1365-2893.2006.00768.x
更新日期:2006-12-01 00:00:00
abstract::Quantitative serology for hepatitis B surface antigen (HBsAg) is a new candidate marker for prediction of clinical outcome. The aim of this study was to investigate the clinical significance of quantifying HBsAg in patients with hepatitis B virus (HBV) infection. A total of 424 patients who tested positive for HBsAg a...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2011.01486.x
更新日期:2011-10-01 00:00:00
abstract::The treatment option in chronic hepatitis B (CHB) patients with persistent low-level viremia despite entecavir or tenofovir monotherapy is unclear. This study investigated the development of hepatocellular carcinoma (HCC) or cirrhosis in hepatitis B e antigen (HBeAg)-positive high viral load CHB patients, according to...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12838
更新日期:2018-05-01 00:00:00
abstract::The non-structural (NS)5A protein of hepatitis C virus (HCV) is cleaved, after translation, by the NS3-encoded zinc-dependent serine proteinase, from the NS4B protein upstream and the NS5B protein downstream. The released, mature NS5A protein is a 56 000 MW phosphoprotein (p56), which also exists within infected cells...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1046/j.1365-2893.1999.00185.x
更新日期:1999-09-01 00:00:00
abstract::Chronic non-A, non-B hepatitis (NANBH) is a common and often progressive liver disease. Based on current serological tests, hepatitis C virus (HCV) infection is responsible for most cases. Interferon-alpha (IFN) treatment at a dose of 3 x 10(6) units given three times per week for 24 weeks has been shown to be effecti...
journal_title:Journal of viral hepatitis
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.1111/j.1365-2893.1994.tb00062.x
更新日期:1994-01-01 00:00:00
abstract::The efficacy of monotherapy with interferon (IFN) (conventional or pegylated IFN) in dialysis patients with chronic hepatitis C remains unclear, although a number of clinical trials have been published addressing this issue. The aim of the study was to evaluate the efficacy and safety of monotherapy by conventional or...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,meta分析
doi:10.1111/j.1365-2893.2007.00907.x
更新日期:2008-02-01 00:00:00
abstract::In hepatitis C virus (HCV) infection, serum viral load is important in the prediction of therapeutic efficacy. However, factors that affect the viral load remain poorly understood. To identify viral genomic elements responsible for the viral load, we investigated samples from a population of Irish women who were iatro...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2005.00645.x
更新日期:2005-11-01 00:00:00
abstract::The aims of the present study were to assess initial virological response (IVR) to adefovir (ADV) treatment for chronic hepatitis B, to identify patients with suboptimal response and to determine the incidence of ADV-resistant mutants. All patients treated with ADV for at least 12 months were evaluated for virological...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2007.00966.x
更新日期:2008-05-01 00:00:00
abstract::This study examined the association between chronic HBV or HCV infection and the risk of extrahepatic cancers. A total of 537 103 adults aged ≥20 years without history of cancer were identified from the Korean National Health Insurance Service-National Sample Cohort between 2003 and 2013. The difference in cancer inci...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13304
更新日期:2020-09-01 00:00:00
abstract::Hepatitis B virus (HBV) infection and its sequelae remain a major health problem for Taiwan. The national hepatitis B (HB) vaccination programme was first launched in 1984 to combat the spread of this infection. This study examined the status of HBV infection amongst students at a Taiwanese university in 2005, 18 year...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2007.00890.x
更新日期:2008-01-01 00:00:00
abstract::Hepatitis C is a complex disease and a significant public health problem. The long-term outcome of HCV infection is difficult to predict, as the virus may be eliminated or may persist to establish a chronic infection. Further investigation is required to clarify factors that determine or influence the outcome of infec...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1046/j.1365-2893.2000.00022.x
更新日期:2000-05-01 00:00:00
abstract::GS-9857, an inhibitor of the hepatitis C virus (HCV) nonstructural protein (NS) 3/4A, demonstrates potent activity against HCV genotypes 1-6 and improved coverage against commonly encountered NS3 resistance-associated variants (RAVs). In this study, the safety, tolerability, antiviral activity and pharmacokinetics (PK...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1111/jvh.12527
更新日期:2016-08-01 00:00:00
abstract::To assess the impact of sequential therapy with adefovir dipivoxil (ADV) and pegylated interferon alfa-2a (PEG-IFN) on virological (serum HBV-DNA) and serological (serum HBsAg) response in 20 consecutive HBeAg-negative patients. Patients received ADV for 20 weeks, then ADV and PEG-IFN for 4 weeks and lastly PEG-IFN fo...
journal_title:Journal of viral hepatitis
pub_type: 临床试验,杂志文章
doi:10.1111/j.1365-2893.2010.01332.x
更新日期:2011-08-01 00:00:00
abstract::Increased infiltration of lymphocytes and induction of damage and destruction of hepatocytes by these lymphocytes are characteristic features of chronic viral hepatitis. As chemokines attract lymphocytes to inflamed tissues, we studied macrophage inflammatory protein (MIP)-3alpha, a CC chemokine, in chronic viral hepa...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1046/j.1365-2893.2002.00354.x
更新日期:2002-05-01 00:00:00
abstract::Hepatitis C virus (HCV) genotype 5 has only been reported in a few countries and treatment response has not been well characterized. Our aim is to present the treatment outcome for HCV genotype 5 patients evaluated at three medical centres in Syria between January 2004 and June 2007. Medical records were reviewed retr...
journal_title:Journal of viral hepatitis
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1111/j.1365-2893.2007.00946.x
更新日期:2008-05-01 00:00:00
abstract::The treatment of hepatitis C is expensive, difficult and arduous from the patient's perspective. It is similarly difficult for the clinician to decide who and when to treat. If hepatitis C is viewed from the liver's perspective we need only treat those patients who will develop the complications of chronic liver disea...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1111/j.1365-2893.2004.00573.x
更新日期:2004-09-01 00:00:00
abstract::Triple therapy using boceprevir or telaprevir remains the reference treatment for genotype 1 chronic hepatitis C in countries where new interferon-free regimens have not yet become available. Antiviral treatment is highly required in cirrhotic patients, but they represent a difficult-to-treat population. We aimed to d...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12433
更新日期:2015-12-01 00:00:00
abstract::Hepatitis C virus (HCV) and HIV are major causes of worldwide disease. We aimed to evaluate the effect of a combined screening programme, which included a risk-assessment questionnaire and rapid tests for point-of-care diagnosis, on screening and new diagnosis rates. This prospective, cluster randomized study was carr...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13413
更新日期:2021-02-01 00:00:00
abstract::Despite the recent progress in antiviral therapy of chronic hepatitis B, clinical experience has shown that antiviral drug resistance is inevitable with the administration of nucleoside analog monotherapy. The long-term persistence of the viral genome in infected cells and the high rate of spontaneous mutation is the ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1111/j.1365-2893.2007.00915.x
更新日期:2007-11-01 00:00:00
abstract::Herpes simplex virus (HSV) hepatitis is a rare and potential life-threatening disease. The diagnosis of HSV hepatitis is hampered by its indifferent clinical presentation, which necessitates confirmatory laboratory data to identify HSV in the affected liver. However, liver biopsies are often contraindicated in the con...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2010.01352.x
更新日期:2011-04-01 00:00:00
abstract::Recently, attention has been focussed on adiponectin and its changes in different types of chronic liver disease. Its relation to hepatic fibrosis and insulin resistance in post-hepatitis liver disease is not clear. The aim of this study was to clarify the adiponectin changes in genotype 4 hepatitis C virus (HCV)-infe...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2009.01096.x
更新日期:2009-10-01 00:00:00
abstract::Intercellular adhesion molecule-1 (ICAM-1) plays an important role in the pathogenesis of viral hepatitis B. Several inflammatory diseases are associated with distinct polymorphisms of the ICAM-1 gene. The aims of this study were to analyse the association of ICAM-1 polymorphisms G241R and K469E with susceptibility to...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2007.00931.x
更新日期:2008-03-01 00:00:00
abstract::Interferon-alpha 2b (IFN-alpha 2b) can exert antiproliferative activity in both normal and malignant liver tissue. To study mechanisms of its antiproliferative action, the activity of the enzymes of adenosine metabolism were investigated. We studied 5'-nucleotidase (an adenosine-producing enzyme) and adenosine deamina...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1046/j.1365-2893.1998.00117.x
更新日期:1998-09-01 00:00:00
abstract::In resource-rich countries, the incidence of and mortality from AIDS has fallen dramatically since the introduction of combination antiretroviral therapy. In contrast, developed countries have observed increases in the public health burden associated with the hepatitis C virus (HCV). We compared past and current trend...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2007.00876.x
更新日期:2007-12-01 00:00:00